Xilio Therapeutics (XLO) Net Cash Flow (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Net Cash Flow data on file, last reported at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 62.09% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $61.3 million (up 13.2% YoY), and the FY2025 full-year result was $82.3 million, up 662.98% from the prior year.
• Net Cash Flow declined to $12.8 million in Q1 2026, from $33.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $40.0 million in Q2 2024 to a low of -$27.1 million in Q1 2023.
• A 5-year average of -$2.8 million and a median of -$15.1 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 119.08% in 2022 and soared 666.57% in 2025, its largest moves.
• Tracing XLO's Net Cash Flow over 5 years: stood at -$18.8 million in 2022, then grew by 19.69% to -$15.1 million in 2023, then surged by 60.42% to -$6.0 million in 2024, then soared by 666.57% to $33.8 million in 2025, then plunged by 62.08% to $12.8 million in 2026.
• Business Quant data shows XLO's Net Cash Flow at $12.8 million in Q1 2026, $33.8 million in Q4 2025, and -$17.8 million in Q3 2025.